Healthcare Equipment and Supplies
Company Overview of TearScience, Inc.
TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was fou...
5151 McCrimmon Parkway
Morrisville, NC 27560
Founded in 2005
Key Executives for TearScience, Inc.
Chief Executive Officer and President
Co-Founder and Chief Technical Officer
Vice President of R & D, Manufacturing & Service
Vice President of Marketing & Market Development
Compensation as of Fiscal Year 2016.
TearScience, Inc. Key Developments
TearScience Names Edward J. Holland to Board of Directors
Aug 8 16
TearScience announced the addition of Edward J. Holland, MD, to its board of directors. Dr. Holland is a leader in the field of Cornea and Ocular Surface Health.
TearScience, Inc. Introduces LipiScan
May 5 16
TearScience announced the release of LipiScan, the first and only dedicated high definition (HD) gland imager that allows eye care professionals (ECPs) to efficiently evaluate meibomian glands in busy practices. The new rapid imager was created with end users in mind. Fast and intuitive, LipiScan harnesses patented dynamic meibomian imaging (DMI) technology to produce high definition images of meibomian glands. LipiScan allows ECPs to assess meibomian gland structure during routine workups in any practice setting. The introduction of LipiScan will allow busy practices to efficiently integrate assessment of meibomian glands and do so at an affordable price. MGD is a prevalent chronic, obstructive and progressive disease that impacts the tear film, visual performance and ocular comfort. LipiFlow treatment for MGD is supported by significant science. A review of 31 sponsored and unsponsored peer-reviewed reports demonstrated that a single LipiFlow treatment typically improves mean meibomian gland secretions while reducing mean patient-reported symptom scores over sustained periods.
TearScience, Inc. Announces Executive Changes
Feb 24 15
TearScience announced that Joseph Boorady will take the helm as President and Chief Executive Officer. Dr. Boorady joins TearScience from Carl Zeiss Meditec, Inc. where he was Senior Vice President of US Sales, Marketing, and Customer Service for all medical products. TearScience current CEO and co-founder Tim Willis, will turn over CEO duties.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 31, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries